NAMSA to Acquire European-Based Medanex Clinic to Expand Early-Stage Preclinical Research Capabilities
Summary
NAMSA also provides Clients the benefit of full continuum development services, including regulatory, reimbursement, quality and clinical research services—proven to reduce timelines up to 30 percent over industry averages. For 12 years, we’ve grown to become a trusted and respected partner for the most challenging surgical studies while remaining customer-oriented and striving for scientific excellence,” stated Medanex CEO, Hadewych Van Hauwermeiren. “With the complementary expertise and resources of NAMSA, we will serve our Clients in an even greater capacity and look forward to joining the world’s leading CRO for Cardiovascular research,” Van Hauwermeiren concluded. Helping medical device Sponsors improve healthcare since 1967, NAMSA is the world’s leading MedTech Contract Research Organization (CRO) offering global end-to-end development services. From medical device testing; regulatory, reimbursement and quality consulting; and clinical research services, NAMSA is the industry’s premier, trusted partner for successful development and commercialization outcomes.